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Introduction
• Tapentadol is a Schedule II opioid with a combination of μ-opioid activity
and norepinephrine reuptake inhibition that is used for the management of
moderate to severe acute and chronic pain.

Figure 1. Ratio of Comparator Opioids Rates to
Tapentadol Rates with 95% Confidence Intervals

• To date, a pattern of relatively low, although not absent, abuse liability has
been found.

• Rates of tapentadol intentional abuse case reports per dosage units
dispensed are lower than hydromorphone, morphine, oxycodone,
and oxymorphone, but greater than hydrocodone.

Methods

• This analysis assesses abuse liability at the opioid molecule level.
Given differences between the molecules, further research is
needed to assess the impact of different formulations (e.g.
immediate release versus extended release; single-entity or
combination-products).

• The abuse and diversion rates for all formulations of tapentadol are
compared to rates for other Schedule II opioids using data from the
Researched Abuse, Diversion and Addiction-Related Surveillance
(RADARS®) System Poison Center and Drug Diversion Programs.

–

Limitations

The RADARS System Poison Center Program obtains data from individuals within
the general population and from healthcare providers who are seeking advice
regarding potential toxic exposures, including exposures to prescription opioids and
stimulants.

• The Poison Center Program relies on spontaneous reports;
therefore, the number of cases is underreported and drug
identification may be inaccurate.

The RADARS System Drug Diversion Program conducts a quarterly survey of law
enforcement investigators on the diversion of prescription opioid and stimulant
products in their jurisdictions.

• Not all parts of the US have prescription drug diversion agencies,
and thus data are subject to under-reporting and regional
differences.

• Cumulative tapentadol rates per population and per dosage units
dispensed are compared to those for hydrocodone, hydromorphone,
morphine, oxycodone, and oxymorphone from October 2011 through
December 2016 using Poisson regression.

Disclosures

Results

The RADARS System is supported by subscriptions from pharmaceutical manufacturers
for surveillance, research and reporting services. RADARS System is the property of
Denver Health and Hospital Authority, a political subdivision of the State of Colorado.
Denver Health retains exclusive ownership of all data, databases and systems.
Subscribers do not participate in data collection or analysis, nor do they have access to
the raw data.

• The ratio of each comparator opioid rate relative to the tapentadol rate is
presented in Figure 1.
• There were 92 intentional abuse exposure case reports (calls) involving
tapentadol products during the study period. Per population, the rate of
tapentadol intentional abuse was significantly lower than all comparator
opioids (p<0.001).
• The rate of tapentadol intentional abuse exposure case reports per
dosage units dispensed was significantly lower than all comparator
opioids (p<0.01) except hydrocodone (p=0.002).
• There were 60 cases of tapentadol diversion during the study period.
Rates of tapentadol diversion per population and per dosage units
dispensed were significantly lower than comparator opioids (p<0.001).

• Population rate findings suggest the overall public health burden of
tapentadol abuse and diversion is low relative to other Schedule II
opioids.
• Diversion of tapentadol is less frequent than other Schedule II
opioid products when accounting for drug utilization (dosage units
dispensed).

• This study included intentional abuse exposures reported to poison
centers and cases of diversion to assess the abuse liability of tapentadol.

–

Conclusions

Note: Values greater than one indicate a rate higher relative to tapentadol. Confidence intervals that do not overlap
1 indicate that the tapentadol rate is significantly different than the comparator rate. Dosage units dispensed data
are based on projections provided by QuintilesIMS™ (Danbury, CT).

